Jeffrey Martini, Ph.D.

Jeffrey Martini, Ph.D.

Chief Scientific OfficeratPalvella Therapeutics· In proxies 2023–2024

Pay in FY2024+204% from the year before · Palvella Therapeutics stock -17.6% the same year

Jeffrey Martini, Ph.D. was paid $1.9M in FY2024 (Dec), up 204%. Palvella Therapeutics stock fell 17.6% that year.

Pay$100 in the stock at the end of FY22 → $14
Pay is from the Summary Compensation Table of each Palvella Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Palvella TherapeuticsPublic company · 3 yr
    • Chief Scientific Officer2023 – Present · 3 yrStock in role +109%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?